Literature DB >> 9267001

Cloning and characterization of rhesus cytomegalovirus glycoprotein B.

R H Kravitz1, K S Sciabica, K Cho, P A Luciw, P A Barry.   

Abstract

Rhesus cytomegalovirus (RhCMV) infection of rhesus macaques is an important model to investigate critical issues of cytomegalovirus biology. To better understand host immunological responses to viral glycoproteins, the glycoprotein B (gB) gene of RhCMV was molecularly cloned, sequenced and characterized. Transcription analysis revealed that RhCMV gB was transcribed as a late gene. The RhCMV gB gene encoded a predicted protein of 854 amino acids that was 60% identical/75% similar to the human CMV (HCMV) gB protein. The region of HCMV gB proposed to be responsible for virus binding to host cells, fusion and cell-to-cell spread was the most highly conserved region with RhCMV gB (74% identity/85% similarity). Conserved elements included 11 of 12 cysteine residues, 14 of 16 potential N-linked glycosylation sites and cross-reactive epitopes. Metabolic labelling experiments demonstrated that RhCMV gB was proteolytically processed similarly to HCMV gB. These results are critical for investigating virus-host relationships in CMV-infected primates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267001     DOI: 10.1099/0022-1317-78-8-2009

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

Review 1.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.

Authors:  Yujuan Yue; Amitinder Kaur; Meghan K Eberhardt; Nadine Kassis; Shan Shan Zhou; Alice F Tarantal; Peter A Barry
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

3.  Pathogenesis of experimental rhesus cytomegalovirus infection.

Authors:  K M Lockridge; G Sequar; S S Zhou; Y Yue; C P Mandell; P A Barry
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

4.  Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule.

Authors:  Thomas R Jones; Shi-Wu Lee; Stephen V Johann; Vladimir Razinkov; Robert J Visalli; Boris Feld; Jonathan D Bloom; John O'Connell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis.

Authors:  Getachew Sequar; William J Britt; Fred D Lakeman; Kristen M Lockridge; Ross P Tarara; Don R Canfield; Shan-Shan Zhou; Murray B Gardner; Peter A Barry
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 6.  Rhesus CMV: an emerging animal model for human CMV.

Authors:  Colin Powers; Klaus Früh
Journal:  Med Microbiol Immunol       Date:  2008-01-11       Impact factor: 3.402

Review 7.  Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.

Authors:  Hannah L Itell; Amitinder Kaur; Jesse D Deere; Peter A Barry; Sallie R Permar
Journal:  Curr Opin Virol       Date:  2017-09-06       Impact factor: 7.090

8.  Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides.

Authors:  Thomas W North; Getachew Sequar; Leroy B Townsend; John C Drach; Peter A Barry
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 9.  Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth.

Authors:  Miranda Li; Alyssa Brokaw; Anna M Furuta; Brahm Coler; Veronica Obregon-Perko; Ann Chahroudi; Hsuan-Yuan Wang; Sallie R Permar; Charlotte E Hotchkiss; Thaddeus G Golos; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.